What is HC Wainwright’s Forecast for Indivior Q1 Earnings?

Indivior PLC (NASDAQ:INDV) – Analysts at HC Wainwright reduced their Q1 2026 earnings estimates for shares of Indivior in a research note issued to investors on Friday, February 27th. HC Wainwright analyst B. Folkes now forecasts that the company will earn $0.67 per share for the quarter, down from their prior estimate of $0.72. HC Wainwright has a “Buy” rating and a $48.00 price target on the stock. The consensus estimate for Indivior’s current full-year earnings is $1.22 per share. HC Wainwright also issued estimates for Indivior’s Q4 2026 earnings at $0.84 EPS and FY2030 earnings at $3.78 EPS.

Several other brokerages have also recently commented on INDV. Morgan Stanley restated an “overweight” rating and set a $36.00 target price on shares of Indivior in a report on Wednesday, December 3rd. Weiss Ratings upgraded Indivior from a “hold (c)” rating to a “buy (b-)” rating in a report on Monday. Northland Securities set a $50.00 price target on Indivior in a research note on Tuesday, January 20th. Finally, Zacks Research cut Indivior from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 13th. Six investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.33.

Indivior Stock Down 3.5%

NASDAQ:INDV opened at $30.87 on Monday. The company has a market cap of $3.86 billion, a P/E ratio of 18.82 and a beta of 0.83. Indivior has a twelve month low of $8.64 and a twelve month high of $38.00. The business has a 50 day moving average price of $34.35 and a two-hundred day moving average price of $30.21.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.17. Indivior had a negative return on equity of 148.76% and a net margin of 16.85%.The company had revenue of $358.00 million during the quarter, compared to analysts’ expectations of $305.62 million.

Insider Activity at Indivior

In other news, Director David E. Wheadon bought 1,771 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was bought at an average price of $35.39 per share, with a total value of $62,675.69. Following the completion of the acquisition, the director owned 14,395 shares of the company’s stock, valued at $509,439.05. This represents a 14.03% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Mark Stejbach bought 775 shares of Indivior stock in a transaction dated Monday, January 5th. The stock was acquired at an average cost of $35.39 per share, with a total value of $27,427.25. Following the transaction, the director owned 16,847 shares of the company’s stock, valued at $596,215.33. This trade represents a 4.82% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased 4,871 shares of company stock valued at $172,385 in the last 90 days.

Institutional Trading of Indivior

Institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. increased its holdings in shares of Indivior by 18.4% during the first quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock worth $79,757,000 after purchasing an additional 1,299,425 shares during the period. Jane Street Group LLC increased its stake in Indivior by 2,597.9% during the 1st quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock worth $9,327,000 after acquiring an additional 958,132 shares during the period. State of New Jersey Common Pension Fund D acquired a new position in Indivior in the 2nd quarter valued at $262,000. Y Intercept Hong Kong Ltd lifted its position in shares of Indivior by 17.4% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 25,443 shares of the company’s stock valued at $375,000 after acquiring an additional 3,769 shares during the period. Finally, Amalgamated Bank bought a new stake in shares of Indivior during the 2nd quarter valued at $61,000. Institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.